Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid use disorder. We are committed to advancing a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of addiction faced by patients, healthcare professionals, payers and society. Braeburn has one mission: to fight the opioid addiction epidemic. The work we are doing can make a difference in the lives of patients who often shoulder the burden of treatment themselves. We aim to reduce stigma by raising awareness that OUD is a chronic brain disease best treated by evidence-based medication-assisted treatment. We are dedicated to developing into a highly effective organization; and through collaboration and commitment we can execute on our mission. For more information about Braeburn, please visit www.braeburnrx.com.

Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.